Diligence memo · auto-generated · as of July 2, 2026

ACCUDIAL Pharmaceutical INC

ACCUDIAL Pharmaceutical INC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

ACCUDIAL Pharmaceutical INC operates in Pharmaceuticals, based in Boca Raton.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

ACCUDIAL Pharmaceutical INC has raised $18M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $5.0M on —.

Most recent recorded round closed around 2014-11-17.

Valuation (modeled)modeled

Provath models ACCUDIAL Pharmaceutical INC at approximately $12M (range $425K–$63M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.06× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 108 months.

Last raise 11.6 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 6.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 65% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 19% of those peers.

Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC.

Peoplefiled

20 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.